{
    "links": "https://www.ycombinator.com/companies/nuntius-therapeutics",
    "name": "Nuntius Therapeutics",
    "headline": "Cell-specific genetic medicines",
    "batch": "W21",
    "description": null,
    "activity_status": "Active",
    "website": "http://www.nuntiustx.com",
    "founded_date": 2021.0,
    "team_size": 2.0,
    "location": "London, United Kingdom",
    "group_partner": "Jared Friedman",
    "group_partner_yc": "https://www.ycombinator.com/people/jared-friedman",
    "company_linkedin": null,
    "company_twitter": null,
    "tags": "industry:gene-therapy; industry:nanomedicine",
    "founders": [],
    "status": true,
    "generated_description": "### Overview of Nuntius Therapeutics\n\n**Nuntius Therapeutics** is a cutting-edge biotech startup founded in **2021**, based in **London, UK**. This company stands at the forefront of the **gene therapy** and **nanomedicine** space, emerging as a notable member of **Y Combinator's W21 batch**. With a lean team of just two passionate employees, Nuntius is focused on revolutionizing the way we approach genetic medicines.\n\n**Mission and Focus**\n\nNuntius is dedicated to developing **cell-specific genetic medicines**, primarily utilizing their innovative **mRNA therapies**. Their mission is straightforward yet monumental: to create transformative genetic treatments for patients suffering from life-threatening diseases. Their current research pipeline targets serious conditions such as **cancer**, **lung diseases**, and **neurodegenerative diseases**.\n\n### The Science Behind Nuntius\n\n1. **Proprietary Delivery Technology**: Nuntius has engineered proprietary, non-immunogenic **nanocarriers** capable of targeting a variety of cell types beyond the liver, which is a significant limitation of many existing delivery systems.\n\n2. **Machine Learning Integration**: The firm's methodologies integrate advanced **machine learning** to select the most effective nanocarrier candidates from a library of millions, ensuring that the mRNA therapeutics have the best possible delivery and efficacy.\n\n3. **Nucleic Acid Engineering**: Nuntius's expertise in **genetic payload engineering** allows them to design mRNA constructs that achieve superior protein expression levels compared to current therapies on the market.\n\n### Leadership and Team\n\nThe company is co-founded by **Benita Nagel (CEO)** and **Albert Kwok (CSO)**, both of whom lead a diverse group of experts, including chemists and biologists specializing in delivery systems, machine learning, and mRNA engineering. Their collaborative atmosphere is bolstered by a group of capable scientific and business advisors.\n\n### Recent Developments\n\nRecently, Nuntius has made waves by partnering with **Taiho Pharmaceutical** to advance mRNA cancer therapies. This collaboration marks a significant step as they bring their proprietary delivery technology into real-world applications.\n\n### Conclusion\n\nIn a nutshell, Nuntius Therapeutics is a dynamic and ambitious player in the biotech realm, committed to pushing the boundaries of genetic medicine. Their innovative approaches and strategic partnerships position them well for impacting how we understand and treat some of the most challenging diseases of our time. To learn more, visit their official website at [Nuntius Therapeutics](http://www.nuntiustx.com).",
    "logo": "https://bookface-images.s3.us-west-2.amazonaws.com/logos/4645689133bdc9f6a4161490b40562bb873852b7.png?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=ASIAQC4NIECAJMV6TLGB%2F20250221%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20250221T191603Z&X-Amz-Expires=3600&X-Amz-Security-Token=IQoJb3JpZ2luX2VjELP%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLXdlc3QtMiJGMEQCIFLa1ybFb1MW3YWarl6N2DZLtQ4R6h64JtRzg2nxAowaAiB3nTk9Wj2wgaQBuQdmXKSYUK01s%2FfzNcIsI%2FpnnVYrDCruAwjc%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F8BEAAaDDAwNjIwMTgxMTA3MiIMbK4eHGyZbeOmKiEOKsIDEgeFqYzoIm9WYPES%2BanLfTcQEGyzIks%2Fal2Lmqxe4p56ewXYsETQE6xKLCXrmvzZNyUDpx5dtkyRoWAO6FYyXXGaPQzEZ3lyFdj%2BxmzYPjn73zyfO0POWT06n60Ss4FWi%2BsXTCqzCDlztmj5P3pe%2BccFf3AJ6Fob0iUEcgWZg86XqS2niw4lXPnalb%2Boq3NuXvHl2oVLzjcW3kqbNIZD4bJeuP%2BaiX3YtJ%2BJXjqRV4JMYzbegC89ld8%2FQ6Niu9GP6iWyA3Ij%2Frc6v9eF94GLnVFmDUIq%2FgOldm3US8WLOYW64cbfEYgRv4%2BZqFOZik7gMqvr0%2BAMO66zctStkeS7pQEndome2HMXzolZnAHIKHa7syJwRucmMBn1qLVqGHDFwDTWD66ZqASdClXaJEb6qKYFGBQM0HPz9IZYPkFD7FlZyifcWNrFEjlM4LJiyAQcunx30b5EMcz8oT7YjYIo5Bb2DOsnIt6uAdkOmUPUmY%2FzM3PmuL6ZYePw7XBzfBYcfiNqZPHWFO6x0%2FmP5sl5TFTspcBFiC1tU5q9L40pvlUpeAHA0lByHoziRM9b9aIUnBzO8cEmGGLYvEv9AlDEIduUMLKL470GOqYBeuzvU%2B1K1xvzamOk1TaDeko%2BJlQ8xUgcguCKvnE%2BpYSn9MQz0SIXrm4hUrSnIO%2FjFoTZ4esBSlXTCkXH%2F6%2BRHttOAoEAfv1XQWO8%2Bsv2qVS97SrODEBLVhY1tfEFQcw%2BZ93GUo5LYHe1U2PubGkf9wTLJ5AZCq5Vr1%2FKLwVlulVfHEhtz4E3fzOL1TPO7tIclZor0kZmzjAwtkky7VHrQVXehNV3Gw%3D%3D&X-Amz-SignedHeaders=host&X-Amz-Signature=4707ce2cd31eebd99bd5d209e1d0629e2fcd92a2df2890212ea4d54eff4010dd",
    "social_links": [],
    "logo_path": "data/logos\\Nuntius_Therapeutics_logo.png"
}